Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany

Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, Krueger H, Greiner W (2015)
The European Journal of Health Economics 16(5): 471-488.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Damm, OliverUniBi; Eichner, Martin; Rose, Markus Andreas; Knuf, Markus; Wutzler, Peter; Liese, Johannes Guenter; Krueger, Hagen; Greiner, WolfgangUniBi
Abstract / Bemerkung
In 2011, intranasally administered live attenuated influenza vaccine (LAIV) was approved in the EU for prophylaxis of seasonal influenza in 2-17-year-old children. Our objective was to estimate the potential epidemiological impact and cost-effectiveness of an LAIV-based extension of the influenza vaccination programme to healthy children in Germany. An age-structured dynamic model of influenza transmission was developed and combined with a decision-tree to evaluate different vaccination strategies in the German health care system. Model inputs were based on published literature or were derived by expert consulting using the Delphi technique. Unit costs were drawn from German sources. Under base-case assumptions, annual routine vaccination of children aged 2-17 years with LAIV assuming an uptake of 50 % would prevent, across all ages, 16 million cases of symptomatic influenza, over 600,000 cases of acute otitis media, nearly 130,000 cases of community-acquired pneumonia, nearly 1.7 million prescriptions of antibiotics and over 165,000 hospitalisations over 10 years. The discounted incremental cost-effectiveness ratio was a,not sign1,228 per quality-adjusted life year gained from a broad third-party payer perspective (including reimbursed direct costs and specific transfer payments), when compared with the current strategy of vaccinating primarily risk groups with the conventional trivalent inactivated vaccine. Inclusion of patient co-payments and indirect costs in terms of productivity losses resulted in discounted 10-year cost savings of a,not sign3.4 billion. In conclusion, adopting universal influenza immunisation of healthy children and adolescents would lead to a substantial reduction in influenza-associated disease at a reasonable cost to the German statutory health insurance system. On the basis of the epidemiological and health economic simulation results, a recommendation of introducing annual routine influenza vaccination of children 2-17 years of age might be taken into consideration.
Germany; transmission model; Dynamic; Cost-effectiveness; Children; Influenza; Vaccination
The European Journal of Health Economics
Page URI


Damm O, Eichner M, Rose MA, et al. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. The European Journal of Health Economics. 2015;16(5):471-488.
Damm, O., Eichner, M., Rose, M. A., Knuf, M., Wutzler, P., Liese, J. G., Krueger, H., et al. (2015). Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. The European Journal of Health Economics, 16(5), 471-488. doi:10.1007/s10198-014-0586-4
Damm, O., Eichner, M., Rose, M. A., Knuf, M., Wutzler, P., Liese, J. G., Krueger, H., and Greiner, W. (2015). Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. The European Journal of Health Economics 16, 471-488.
Damm, O., et al., 2015. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. The European Journal of Health Economics, 16(5), p 471-488.
O. Damm, et al., “Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany”, The European Journal of Health Economics, vol. 16, 2015, pp. 471-488.
Damm, O., Eichner, M., Rose, M.A., Knuf, M., Wutzler, P., Liese, J.G., Krueger, H., Greiner, W.: Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. The European Journal of Health Economics. 16, 471-488 (2015).
Damm, Oliver, Eichner, Martin, Rose, Markus Andreas, Knuf, Markus, Wutzler, Peter, Liese, Johannes Guenter, Krueger, Hagen, and Greiner, Wolfgang. “Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany”. The European Journal of Health Economics 16.5 (2015): 471-488.

13 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
Kim YK, Song JY, Jang H, Kim TH, Koo H, Varghese L, Han E., Pharmacoeconomics 36(12), 2018
PMID: 30251078
Current prospects and future challenges for nasal vaccine delivery.
Yusuf H, Kett V., Hum Vaccin Immunother 13(1), 2017
PMID: 27936348
Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model.
Gerlier L, Lamotte M, Grenèche S, Lenne X, Carrat F, Weil-Olivier C, Damm O, Schwehm M, Eichner M., Appl Health Econ Health Policy 15(2), 2017
PMID: 27943165
Direct and indirect effects of influenza vaccination.
Eichner M, Schwehm M, Eichner L, Gerlier L., BMC Infect Dis 17(1), 2017
PMID: 28441935
Cost Effectiveness of Influenza Vaccine for U.S. Children: Live Attenuated and Inactivated Influenza Vaccine.
Shim E, Brown ST, DePasse J, Nowalk MP, Raviotta JM, Smith KJ, Zimmerman RK., Am J Prev Med 51(3), 2016
PMID: 27079638
Recent Developments in Pediatric Community-Acquired Pneumonia.
McCulloh RJ, Patel K., Curr Infect Dis Rep 18(5), 2016
PMID: 26960931
Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium.
Gerlier L, Lamotte M, Dos Santos Mendes S, Damm O, Schwehm M, Eichner M., Paediatr Drugs 18(4), 2016
PMID: 27272706
Seasonal influenza vaccination for children in Thailand: a cost-effectiveness analysis.
Meeyai A, Praditsitthikorn N, Kotirum S, Kulpeng W, Putthasri W, Cooper BS, Teerawattananon Y., PLoS Med 12(5), 2015
PMID: 26011712
A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E., Infect Dis Ther 4(4), 2015
PMID: 26350238

89 References

Daten bereitgestellt von Europe PubMed Central.

The impact of influenza on working days lost: a review of the literature.
Keech M, Beardsworth P., Pharmacoeconomics 26(11), 2008
PMID: 18850761
The annual impact of seasonal influenza in the US: measuring disease burden and costs.
Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB., Vaccine 25(27), 2007
PMID: 17544181
[Public health costs of influenza in Germany 1996- a cost-of-illness analysis]
Szucs T, Behrens M, Volmer T., Med. Klin. (Munich) 96(2), 2001
PMID: 11253284
Clinical manifestations and socio-economic impact of influenza among healthy children in the community.
Esposito S, Cantarutti L, Molteni CG, Daleno C, Scala A, Tagliabue C, Pelucchi C, Giaquinto C, Principi N., J. Infect. 62(5), 2011
PMID: 21414357
Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis.
Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, Simmerman JM, Gordon A, Sato M, Howie S, Krishnan A, Ope M, Lindblade KA, Carosone-Link P, Lucero M, Ochieng W, Kamimoto L, Dueger E, Bhat N, Vong S, Theodoratou E, Chittaganpitch M, Chimah O, Balmaseda A, Buchy P, Harris E, Evans V, Katayose M, Gaur B, O'Callaghan-Gordo C, Goswami D, Arvelo W, Venter M, Briese T, Tokarz R, Widdowson MA, Mounts AW, Breiman RF, Feikin DR, Klugman KP, Olsen SJ, Gessner BD, Wright PF, Rudan I, Broor S, Simoes EA, Campbell H., Lancet 378(9807), 2011
PMID: 22078723
High costs of influenza: Direct medical costs of influenza disease in young children.
Fairbrother G, Cassedy A, Ortega-Sanchez IR, Szilagyi PG, Edwards KM, Molinari NA, Donauer S, Henderson D, Ambrose S, Kent D, Poehling K, Weinberg GA, Griffin MR, Hall CB, Finelli L, Bridges C, Staat MA; New Vaccine Surveillance Network (NVSN), Clay CA, Keckley E, Kent D, Whitehead N, Zhu Y, Albertin C, Lofthus G, Schnabel K, Florian V, Holloway M, Jamison L, Tabangin ME., Vaccine 28(31), 2010
PMID: 20576536
Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection.
Ampofo K, Gesteland PH, Bender J, Mills M, Daly J, Samore M, Byington C, Pavia AT, Srivastava R., Pediatrics 118(6), 2006
PMID: 17142526
The underrecognized burden of influenza in young children.
Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, Bridges CB, Grijalva CG, Zhu Y, Bernstein DI, Herrera G, Erdman D, Hall CB, Seither R, Griffin MR; New Vaccine Surveillance Network., N. Engl. J. Med. 355(1), 2006
PMID: 16822994
Burden of influenza in children in the community.
Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, Kainulainen L, Puhakka T, Jartti T, Toikka P, Lehtinen P, Routi T, Juven T., J. Infect. Dis. 190(8), 2004
PMID: 15378427
Burden of influenza in healthy children and their households.
Principi N, Esposito S, Gasparini R, Marchisio P, Crovari P; Flu-Flu Study Group., Arch. Dis. Child. 89(11), 2004
PMID: 15499051
Seasonal influenza: the burden of disease in children.
Fraaij PL, Heikkinen T., Vaccine 29(43), 2011
PMID: 21820476
Complications of viral influenza.
Rothberg MB, Haessler SD, Brown RB., Am. J. Med. 121(4), 2008
PMID: 18374680
[Prophylactic influenza vaccination: what is the situation in Germany?]
Wutzler P., Dtsch. Med. Wochenschr. 131(9), 2006
PMID: 16493571
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.
Osterholm MT, Kelley NS, Sommer A, Belongia EA., Lancet Infect Dis 12(1), 2011
PMID: 22032844
Duration of protection provided by live attenuated influenza vaccine in children.
Ambrose CS, Yi T, Walker RE, Connor EM., Pediatr. Infect. Dis. J. 27(8), 2008
PMID: 18600188
Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.
Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S, Rajamohanan KP, Narayanan SN, Kirubakaran C, Rappaport R, Razmpour A, Gruber WC, Forrest BD; Pan-Asian CAIV-T Pediatric Efficacy Trial Network., Pediatr. Infect. Dis. J. 26(7), 2007
PMID: 17596805
A survey of children's preferences for influenza vaccine attributes.
Flood EM, Ryan KJ, Rousculp MD, Beusterien KM, Block SL, Hall MC, Mahadevia PJ., Vaccine 29(26), 2011
PMID: 21510993



Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children.
Usonis V, Anca I, Andre F, Chlibek R, Ivaskeviciene I, Mangarov A, Meszner Z, Prymula R, Simurka P, Tamm E, Tesovic G, Central European Vaccination Advisory Group ., BMC Infect. Dis. 10(), 2010
PMID: 20546586

Mitteilungen der Sächsischen Impfkommission (SIKO)
Bigl S., 2010

Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial.
Loeb M, Russell ML, Moss L, Fonseca K, Fox J, Earn DJ, Aoki F, Horsman G, Van Caeseele P, Chokani K, Vooght M, Babiuk L, Webby R, Walter SD., JAMA 303(10), 2010
PMID: 20215608
The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly.
Ghendon YZ, Kaira AN, Elshina GA., Epidemiol. Infect. 134(1), 2005
PMID: 16316494
Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence.
Jordan R, Connock M, Albon E, Fry-Smith A, Olowokure B, Hawker J, Burls A., Vaccine 24(8), 2005
PMID: 16298026
The Japanese experience with vaccinating schoolchildren against influenza.
Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M., N. Engl. J. Med. 344(12), 2001
PMID: 11259722
Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia.
Rudenko LG, Slepushkin AN, Monto AS, Kendal AP, Grigorieva EP, Burtseva EP, Rekstin AR, Beljaev AL, Bragina VE, Cox N., J. Infect. Dis. 168(4), 1993
PMID: 8376833
The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study.
Rose MA, Damm O, Greiner W, Knuf M, Wutzler P, Liese JG, Kruger H, Wahn U, Schaberg T, Schwehm M, Kochmann TF, Eichner M., BMC Infect. Dis. 14(), 2014
PMID: 24450996


Social contacts and mixing patterns relevant to the spread of infectious diseases.
Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, Massari M, Salmaso S, Tomba GS, Wallinga J, Heijne J, Sadkowska-Todys M, Rosinska M, Edmunds WJ., PLoS Med. 5(3), 2008
PMID: 18366252
Seasonal influenza in the United States, France, and Australia: transmission and prospects for control.
Chowell G, Miller MA, Viboud C., Epidemiol. Infect. 136(6), 2007
PMID: 17634159
Time lines of infection and disease in human influenza: a review of volunteer challenge studies.
Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, Valleron AJ., Am. J. Epidemiol. 167(7), 2008
PMID: 18230677
Estimating the impact of childhood influenza vaccination programmes in England and Wales.
Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ., Vaccine 26(41), 2008
PMID: 18647634
Oil-in-water emulsion adjuvant with influenza vaccine in young children.
Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R., N. Engl. J. Med. 365(15), 2011
PMID: 21995388
Vaccines for preventing influenza in the elderly.
Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE., Cochrane Database Syst Rev (2), 2010
PMID: 20166072
Comparative efficacy of inactivated and live attenuated influenza vaccines.
Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC., N. Engl. J. Med. 361(13), 2009
PMID: 19776407
Vaccines for preventing influenza in healthy children
Jefferson T, Rivetti A, Harnden A, Di C, Demicheli V., 2008
Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.
Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J., Vaccine 27(7), 2008
PMID: 19095024
Vaccines for preventing influenza in healthy children
Jefferson T, Rivetti A, Di C, Demicheli V, Ferroni E., 2012

Vaccination coverage rates in eleven European countries during two consecutive influenza seasons.
Blank PR, Schwenkglenks M, Szucs TD., J. Infect. 58(6), 2009
PMID: 19446340
Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom.
Meier CR, Napalkov PN, Wegmuller Y, Jefferson T, Jick H., Eur. J. Clin. Microbiol. Infect. Dis. 19(11), 2000
PMID: 11152308
The incidence, natural history and associated outcomes of influenza-like illness and clinical influenza in Italy.
Sessa A, Costa B, Bamfi F, Bettoncelli G, D'Ambrosio G., Fam Pract 18(6), 2001
PMID: 11739352
New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality.
Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, Schraeder P, Welte T, Hoeffken G., Thorax 64(12), 2009
PMID: 19454409
How deadly is seasonal influenza-associated pneumonia? The German Competence Network for Community-Acquired Pneumonia.
von Baum H, Schweiger B, Welte T, Marre R, Suttorp N, Pletz MW, Ewig S; CAPNETZ Study Group, Rohde G, Hauptmeier B, Schaberg T, Hering I, Dalhoff K, Heyer P, Schumann C, Bauer T, Kunitz F, Schutte H, Tessmer A, Rademacher J, Gillissen A, Drewelow B, Majcher-Peszynska J, Kruger S, Bals R, Martus P, Illmann T, Wallner M, Barten G, Gosman L., Eur. Respir. J. 37(5), 2010
PMID: 20817703
Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries.
Butler CC, Hood K, Verheij T, Little P, Melbye H, Nuttall J, Kelly MJ, Molstad S, Godycki-Cwirko M, Almirall J, Torres A, Gillespie D, Rautakorpi U, Coenen S, Goossens H., BMJ 338(), 2009
PMID: 19549995
Arzneimittelmarkt: Selbstmedikation im Fokus
Zok K., 2006
[Differences in antibiotic prescribing between general practitioners and pediatricians in Hesse, Germany].
Abbas S, Ihle P, Heymans L, Kupper-Nybelen J, Schubert I., Dtsch. Med. Wochenschr. 135(37), 2010
PMID: 20824600
Burden of disease in hospitalized RSV-positive children in Germany.
Weigl JA, Puppe W, Rockahr S, Schmitt HJ., Klin Padiatr 214(6), 2002
PMID: 12424681
Management of patients with community-acquired pneumonia in a primary care hospital: a critical evaluation.
Ewig S, Seifert K, Kleinfeld T, Goke N, Schafer H., Respir Med 94(6), 2000
PMID: 10921759




The friction cost method for measuring indirect costs of disease.
Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L., J Health Econ 14(2), 1995
PMID: 10154656



Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia.
Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C., Pharmacoeconomics 17(6), 2000
PMID: 10977398
Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.
Talbird SE, Brogan AJ, Winiarski AP, Sander B., Am J Health Syst Pharm 66(5), 2009
PMID: 19233995
[The Quality of Life Questionnaire EQ-5D: modelling and norm values for the general population].
Hinz A, Klaiberg A, Brahler E, Konig HH., Psychother Psychosom Med Psychol 56(2), 2006
PMID: 16453241
Schätzung der Influenza-bedingten Todesfälle während der Saison 2008/09 und der pandemischen Saison 2009/10
Influenza associated excess mortality in Germany, 1985-2001.
Zucs P, Buchholz U, Haas W, Uphoff H., Emerg Themes Epidemiol 2(), 2005
PMID: 15969758
Economic evidence of influenza vaccination in children.
Savidan E, Chevat C, Marsh G., Health Policy 86(2-3), 2007
PMID: 18054109
Cost-effectiveness of influenza vaccination in high-risk children in Argentina.
Dayan GH, Nguyen VH, Debbag R, Gomez R, Wood SC., Vaccine 19(30), 2001
PMID: 11457546
An economic analysis of annual influenza vaccination of children.
Meltzer MI, Neuzil KM, Griffin MR, Fukuda K., Vaccine 23(8), 2005
PMID: 15620473
Potential cost savings attributable to influenza vaccination of school-aged children.
White T, Lavoie S, Nettleman MD., Pediatrics 103(6), 1999
PMID: 10353970
Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age.
Marchetti M, Kuhnel UM, Colombo GL, Esposito S, Principi N., Hum Vaccin 3(1), 2007
PMID: 17245134
Cost-effectiveness of influenza vaccination of healthy children.
Salo H, Kilpi T, Sintonen H, Linna M, Peltola V, Heikkinen T., Vaccine 24(23), 2006
PMID: 16678945
Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada.
Skowronski DM, Woolcott JC, Tweed SA, Brunham RC, Marra F., Vaccine 24(19), 2006
PMID: 16423432
Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ., Vaccine 26(23), 2008
PMID: 18462851
Health benefits, risks, and cost-effectiveness of influenza vaccination of children.
Prosser LA, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari NA, Schwartz B, Thompson WW, Fukuda K, Lieu TA., Emerging Infect. Dis. 12(10), 2006
PMID: 17176570
Economic impact of influenza vaccination in preschool children.
Cohen GM, Nettleman MD., Pediatrics 106(5), 2000
PMID: 11061762
Public health and economic benefits of new pediatric influenza vaccination programs in Argentina.
Giglio N, Gentile A, Lees L, Micone P, Armoni J, Reygrobellet C, Crepey P., Hum Vaccin Immunother 8(3), 2012
PMID: 22330959
Population-wide benefits of routine vaccination of children against influenza.
Weycker D, Edelsberg J, Halloran ME, Longini IM Jr, Nizam A, Ciuryla V, Oster G., Vaccine 23(10), 2005
PMID: 15652671
Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study.
Jackson LA, Neuzil KM, Baggs J, Davis RL, Black S, Yamasaki KM, Belongia E, Zangwill KM, Mullooly J, Nordin J, Marcy SM, DeStefano F., Pediatrics 118(5), 2006
PMID: 17079576


Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®


PMID: 24859492
PubMed | Europe PMC

Suchen in

Google Scholar